Form 4: ImmunityBio Director Wesley Clark Granted Stock Options Under Equity Plan

ImmunityBio, Inc. Director Wesley Clark was granted 162,786 stock options with an exercise price of $2.84, vesting by June 2026, as part of a pre-arranged compensation plan.

Summary

• ImmunityBio, Inc. Director Wesley Clark received a grant of 162,786 stock options on June 18, 2025.
• The stock options have an exercise price of $2.84 per share.
• One hundred percent (100%) of the granted shares are set to vest on the earlier of June 18, 2026, or the date immediately preceding ImmunityBio's next annual meeting of stockholders.
• Vesting is contingent upon Mr. Clark's continuous service as a Service Provider, as defined in the Issuer's 2025 Equity Incentive Plan.
• The options are exercisable until their expiration date of June 18, 2035.
• This transaction was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-scheduled arrangement for the acquisition of equity securities.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event that aligns management interests with shareholders, which is generally viewed as neutral to slightly positive. It does not indicate any significant positive or negative operational or financial news.

Positives

• The grant of stock options aligns the financial interests of Director Wesley Clark with those of ImmunityBio shareholders, as the options' value increases with the company's stock price.
• The transaction was conducted under a Rule 10b5-1(c) plan, demonstrating a pre-arranged and transparent approach to insider equity transactions.

Negatives

• The issuance of new stock options could lead to minor future dilution for existing shareholders if and when the options are exercised, although this is a standard component of director compensation.

Risks

• The vesting of the 162,786 stock options is conditional on Director Wesley Clark's continued service as a Service Provider until the specified vesting date (earlier of June 18, 2026, or the date preceding the next annual meeting of stockholders). Failure to meet this condition would result in forfeiture of unvested options.
• The ultimate value of the stock options is dependent on ImmunityBio's future stock performance. If the common stock price does not rise above the $2.84 exercise price, the options may expire worthless.

Future Outlook

The stock options are subject to vesting on the earlier of June 18, 2026, or the date immediately preceding the Issuer's next annual meeting of stockholders, contingent on the reporting person's continued service.

Industry Context

This Form 4 filing details a routine equity compensation grant to a director, which is a common practice across publicly traded companies in various industries, including biotechnology, to align director incentives with shareholder value creation.

Related Party Transactions

• The grant of stock options to Director Wesley Clark can be considered a related party transaction as it involves compensation to a member of the company's board of directors. However, this is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: Minor potential future dilution if options are exercised, but also improved alignment of director incentives with shareholder value.
• Employees: No direct impact mentioned, but the transaction is under the Issuer's 2025 Equity Incentive Plan, which may also apply to other service providers.

Next Steps

• Vesting of the 162,786 stock options on the earlier of June 18, 2026, or the date immediately preceding the Issuer's next annual meeting of stockholders, subject to continued service.
• Potential exercise of the stock options by Director Wesley Clark before the expiration date of June 18, 2035.

Key Dates

Keywords

ImmunityBio, IBRX, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Incentive Plan, Wesley Clark, SEC Filing, Rule 10b5-1